NIH study completes subject enrolment for Brii Biosciences’ Covid-19 antibodies
Brii Biosciences has announced that ACTIV-2 clinical trial of the National Institutes of Health (NIH) in the US closed enrolment for the Phase III part that will evaluate BRII-196 plus BRII-198 for Covid-19 treatment.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.